Suchergebnisse
Filter
13 Ergebnisse
Sortierung:
Needlework: The Lifestyle of Female Drug Injectors
In: Journal of drug issues: JDI, Band 28, Heft 1, S. 77-90
ISSN: 1945-1369
Participant observation was used to study the lifestyles of female drug injectors in Glasgow. Twenty-six women were interviewed in-depth at the end of the observation period. The results reveal how women become involved in drug use, the ways in which they finance their drug use, and their relationships with friends, partners and children. The efforts the women made to give up their use of drugs is discussed along with the difficulties involved in their attempts to do so. Overall, the findings refute the stereotypical view of women drug users as inadequate individuals. The evidence provided indicates that the lifestyle which evolves from the use of drugs offers an arena in which the women are able to find a degree of independence and purpose otherwise missing from their lives and which makes their drug-using lifestyle attractive even when disadvantages become apparent.
Visual Versus Written Cues: A Comparison of Drug Injectors' Responses. Have Surveys Using the Written Word Underestimated Risk Behaviors for Hepatitis C?
In: Substance use & misuse: an international interdisciplinary forum, Band 45, Heft 10, S. 1491-1508
ISSN: 1532-2491
Recovery From Heroin Or Alcohol Dependence: A Qualitative Account of the Recovery Experience in Glasgow
In: Journal of drug issues: JDI, Band 41, Heft 3, S. 359-377
ISSN: 1945-1369
While it is increasingly recognized that recovery from dependent use of heroin or alcohol is possible, little is known about the long-term process of recovery. A study in Glasgow, Scotland used interviews and self-completed questionnaires to investigate the recovery journeys of former problematic users of heroin or alcohol. Qualitative data showed that recovery was understood as including but transcending freedom from dependence, and that most participants saw their own recovery as an ongoing process rather than a time-limited milestone. Motivating factors were usually negative personal experiences—with former heroin users more likely to cite "the lifestyle" and former alcohol users their behavior and health problems - and more positively around issues of personal identity. Social factors were often cited as key in sustaining recovery, especially peer support. An understanding of the views and perceptions of those who have experienced recovery from dependent use of alcohol or heroin can help to develop and improve recovery services and support.
Exploring Associations Between Perceived HCV Status and Injecting Risk Behaviors Among Recent Initiates to Injecting Drug Use in Glasgow
In: Substance use & misuse: an international interdisciplinary forum, Band 43, Heft 3-4, S. 375-388
ISSN: 1532-2491
Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland
In: Fraser , H , Mukandavire , C , Martin , N , Goldberg , D , Palmateer , N , Munro , A , Taylor , A , Hickman , M , Hutchinson , S & Vickerman , P 2018 , ' Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland ' , Addiction , vol. 113 , no. 11 , pp. 2118-2131 . https://doi.org/10.1111/add.14267
Background and Aims: To reduce hepatitis C virus (HCV) transmission among people who inject drugs (PWID), Scottish Government-funded national strategies, launched in 2008, promoted scaling-up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some increases in HCV treatment. We test whether observed decreases in HCV incidence post-2008 can be attributed to this intervention scale-up. Design: A dynamic HCV transmission model amongst PWID incorporating intervention scale-up and observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence data for 2008/09. Setting: Scotland, UK Participants: PWID Measurements: Model projections from 2008-2015 were compared with data to test whether they were consistent with observed decreases in HCV incidence amongst PWID while incorporating the observed intervention scale-up, and to determine the impact of scaling-up interventions on incidence. Findings: Without fitting to epidemiological data post-2008/09, the model incorporating observed intervention scale-up agreed with observed decreases in HCV incidence amongst PWID between 2008-2015, suggesting HCV incidence decreased by 61.3% (95% credibility interval 45.1-75.3%) from 14.2/100pyrs (9.0-20.7) to 5.5/100pyrs (2.9-9.2). On average, each model fit lay within 84% (10.1/12) of the confidence bounds for the 12 incidence data points which the model was compared against. We estimate that scale-up of interventions (OST+NSP+HCV treatment) and decreases in high-risk behaviour from 2008-2015 resulted in a 33.9% (23.8-44.6%) decrease in incidence, with the remainder (27.4% (17.6-37.0%)) explained by historical changes in OST+NSP coverage and risk pre-2008. Projections suggest scaling-up of all interventions post-2008 averted 1,492 (657-2,646) infections over 7-years, with 1,016 (308-1,996), 404 (150-836) and 72 (27-137) due to scale-up of OST+NSP, decreases in high-risk behaviour, and HCV treatment, respectively. Conclusions: Most of the decline in hepatitis C virus (HCV) incidence in Scotland between 2008-2015 appears to be attributable to intervention scale-up (opioid substitution therapy and needle and syringe provision) due to government strategies on HCV and drugs.
BASE
Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland
Background and Aims: To reduce hepatitis C virus (HCV) transmission among people who inject drugs (PWID), Scottish Government‐funded national strategies, launched in 2008, promoted scaling‐up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some increases in HCV treatment. We test whether observed decreases in HCV incidence post‐2008 can be attributed to this intervention scale‐up. Design: A dynamic HCV transmission model among PWID incorporating intervention scale‐up and observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence data for 2008/09. Setting: Scotland, UK. Participants: PWID. Measurements: Model projections from 2008 to 2015 were compared with data to test whether they were consistent with observed decreases in HCV incidence among PWID while incorporating the observed intervention scale‐up, and to determine the impact of scaling‐up interventions on incidence. Findings: Without fitting to epidemiological data post‐2008/09, the model incorporating observed intervention scale‐up agreed with observed decreases in HCV incidence among PWID between 2008 and 2015, suggesting that HCV incidence decreased by 61.3% [95% credibility interval (CrI) = 45.1–75.3%] from 14.2/100 person‐years (py) (9.0–20.7) to 5.5/100 py (2.9–9.2). On average, each model fit lay within 84% (10.1/12) of the confidence bounds for the 12 incidence data points against which the model was compared. We estimate that scale‐up of interventions (OST + NSP + HCV treatment) and decreases in high‐risk behaviour from 2008 to 2015 resulted in a 33.9% (23.8–44.6%) decrease in incidence, with the remainder [27.4% (17.6–37.0%)] explained by historical changes in OST + NSP coverage and risk pre‐2008. Projections suggest that scaling‐up of all interventions post‐2008 averted 1492 (657–2646) infections over 7 years, with 1016 (308–1996), 404 (150–836) and 72 (27–137) due to scale‐up of OST + NSP, decreases in high‐risk behaviour and HCV treatment, respectively. Conclusions: Most of the decline in hepatitis C virus (HCV) incidence in Scotland between 2008 and 2015 appears to be attributable to intervention scale‐up (opioid substitution therapy and needle and syringe provision) due to government strategies on HCV and drugs.
BASE
Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions
In: Palmateer , N E , Taylor , A , Goldberg , D J , Munro , A , Aitken , C , Shepherd , S J , McAllister , G , Gunson , R & Hutchinson , S J 2014 , ' Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions ' PLoS ONE , vol 9 , no. 8 , e104515 . DOI:10.1371/journal.pone.0104515
Background: Government policy has precipitated recent changes in the provision of harm reduction interventions injecting equipment provision (IEP) and opiate substitution therapy (OST) - for people who inject drugs (PWID) in Scotland. We sought to examine the potential impact of these changes on hepatitis C virus (HCV) transmission among PWID. Methods and Findings: We used a framework to triangulate different types of evidence: 'group-level/ecological' and 'individual-level'. Evidence was primarily generated from bio-behavioural cross-sectional surveys of PWID, undertaken during 2008-2012. Individuals in the window period (1-2 months) where the virus is present, but antibodies have not yet been formed, were considered to have recent infection. The survey data were supplemented with service data on the provision of injecting equipment and OST. Ecological analyses examined changes in intervention provision, self-reported intervention uptake, self-reported risk behaviour and HCV incidence; individual-level analyses investigated relationships within the pooled survey data. Nearly 8,000 PWID were recruited in the surveys. We observed a decline in HCV incidence, per 100 person-years, from 13.6 (95% CI: 8.1-20.1) in 2008-09 to 7.3 (3.0-12.9) in 2011-12; a period during which increases in the coverage of OST and IEP, and decreases in the frequency of injecting and sharing of injecting equipment, were observed. Individual-level evidence demonstrated that combined high coverage of needles/syringes and OST were associated with reduced risk of recent HCV in analyses that were unweighted (AOR 0.29, 95% CI 0.11-0.74) and weighted for frequency of injecting (AOR(w) 0.05, 95% CI 0.01-0.18). We estimate the combination of harm reduction interventions may have averted 1400 new HCV infections during 2008-2012. Conclusions: This is the first study to demonstrate that impressive reductions in HCV incidence can be achieved among PWID over a relatively short time period through high coverage of a combination of interventions.
BASE
Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions
In: Palmateer , N E , Taylor , A , Goldberg , D J , Munro , A , Aitken , C , Shepherd , S J , McAllister , G , Gunson , R & Hutchinson , S J 2014 , ' Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions ' , PLoS ONE , vol. 9 , no. 8 , e104515 . https://doi.org/10.1371/journal.pone.0104515
Background Government policy has precipitated recent changes in the provision of harm reduction interventions – injecting equipment provision (IEP) and opiate substitution therapy (OST) – for people who inject drugs (PWID) in Scotland. We sought to examine the potential impact of these changes on hepatitis C virus (HCV) transmission among PWID. Methods and Findings We used a framework to triangulate different types of evidence: 'group-level/ecological' and 'individual-level'. Evidence was primarily generated from bio-behavioural cross-sectional surveys of PWID, undertaken during 2008-2012. Individuals in the window period (1–2 months) where the virus is present, but antibodies have not yet been formed, were considered to have recent infection. The survey data were supplemented with service data on the provision of injecting equipment and OST. Ecological analyses examined changes in intervention provision, self-reported intervention uptake, self-reported risk behaviour and HCV incidence; individual-level analyses investigated relationships within the pooled survey data. Nearly 8,000 PWID were recruited in the surveys. We observed a decline in HCV incidence, per 100 person-years, from 13.6 (95% CI: 8.1–20.1) in 2008–09 to 7.3 (3.0–12.9) in 2011–12; a period during which increases in the coverage of OST and IEP, and decreases in the frequency of injecting and sharing of injecting equipment, were observed. Individual-level evidence demonstrated that combined high coverage of needles/syringes and OST were associated with reduced risk of recent HCV in analyses that were unweighted (AOR 0.29, 95%CI 0.11–0.74) and weighted for frequency of injecting (AORw 0.05, 95%CI 0.01–0.18). We estimate the combination of harm reduction interventions may have averted 1400 new HCV infections during 2008–2012. Conclusions This is the first study to demonstrate that impressive reductions in HCV incidence can be achieved among PWID over a relatively short time period through high coverage of a combination of interventions.
BASE
Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions
Background Government policy has precipitated recent changes in the provision of harm reduction interventions – injecting equipment provision (IEP) and opiate substitution therapy (OST) – for people who inject drugs (PWID) in Scotland. We sought to examine the potential impact of these changes on hepatitis C virus (HCV) transmission among PWID. Methods and Findings We used a framework to triangulate different types of evidence: 'group-level/ecological' and 'individual-level'. Evidence was primarily generated from bio-behavioural cross-sectional surveys of PWID, undertaken during 2008-2012. Individuals in the window period (1–2 months) where the virus is present, but antibodies have not yet been formed, were considered to have recent infection. The survey data were supplemented with service data on the provision of injecting equipment and OST. Ecological analyses examined changes in intervention provision, self-reported intervention uptake, self-reported risk behaviour and HCV incidence; individual-level analyses investigated relationships within the pooled survey data. Nearly 8,000 PWID were recruited in the surveys. We observed a decline in HCV incidence, per 100 person-years, from 13.6 (95% CI: 8.1–20.1) in 2008–09 to 7.3 (3.0–12.9) in 2011–12; a period during which increases in the coverage of OST and IEP, and decreases in the frequency of injecting and sharing of injecting equipment, were observed. Individual-level evidence demonstrated that combined high coverage of needles/syringes and OST were associated with reduced risk of recent HCV in analyses that were unweighted (AOR 0.29, 95%CI 0.11–0.74) and weighted for frequency of injecting (AORw 0.05, 95%CI 0.01–0.18). We estimate the combination of harm reduction interventions may have averted 1400 new HCV infections during 2008–2012. Conclusions This is the first study to demonstrate that impressive reductions in HCV incidence can be achieved among PWID over a relatively short time period through high coverage of a combination of interventions.
BASE
Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy:Scotland's experience
In: Hutchinson , S J , Dillon , J F , Fox , R , McDonald , S A , Innes , H A , Weir , A , McLeod , A , Aspinall , E J , Palmateer , N E , Taylor , A , Munro , A , Valerio , H , Brown , G & Goldberg , D J 2015 , ' Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy : Scotland's experience ' International Journal of Drug Policy , vol 26 , no. 11 , pp. 1041-1049 . DOI:10.1016/j.drugpo.2015.05.019
Seven years have elapsed since the Scottish Government launched its Hepatitis C Action Plan - a Plan to improve services to prevent transmission of infection, particularly among people who inject drugs (PWID), identify those infected and ensure those infected receive optimal treatment. The Plan was underpinned by industrial scale funding (around £100 million, in addition to the general NHS funding, will have been invested by 2015), and a web of accountable national and local multi-disciplinary multi-agency networks responsible for the planning, development and delivery of services. Initiatives ranged from the introduction of testing in specialist drug services through finger-prick blood sampling by non-clinical staff, to the setting of government targets to ensure rapid scale-up of antiviral therapy. The Plan was informed by comprehensive national monitoring systems, indicating the extent of the problem not just in terms of numbers infected, diagnosed and treated but also the more penetrative data on the number advancing to end-stage liver disease and death, and also through compelling modelling work demonstrating the potential beneficial impact of scaling-up therapy and the mounting cost of not acting. Achievements include around 50% increase in the proportion of the infected population diagnosed (38% to 55%); a sustained near two-and-a-half fold increase in the annual number of people initiated onto therapy (470 to 1050) with more pronounced increases among PWID (300 to 840) and prisoners (20 to 140); and reversing of an upward trend in the overall number of people living with chronic infection. The Action Plan has demonstrated that a Government-backed, coordinated and invested approach can transform services and rapidly improve the lives of thousands. Cited as "an impressive example of a national strategy" by the Global Commission on Drug Policy, the Scottish Plan has also provided fundamental insights of international relevance into the management of HCV among PWID.
BASE
Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy:Scotland's experience
In: Hutchinson , S J , Dillon , J F , Fox , R , McDonald , S A , Innes , H , Weir , A , McLeod , A , Aspinall , E J , Palmateer , N E , Taylor , A , Munro , A , Valerio , H , Brown , G & Goldberg , D 2015 , ' Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy : Scotland's experience ' , International Journal of Drug Policy , vol. 26 , no. 11 , pp. 1041-1049 . https://doi.org/10.1016/j.drugpo.2015.05.019
Seven years have elapsed since the Scottish Government launched its Hepatitis C Action Plan – a Plan to improve services to prevent transmission of infection, particularly among people who inject drugs (PWID), identify those infected and ensure those infected receive optimal treatment. The Plan was underpinned by industrial scale funding (around £100 million, in addition to the general NHS funding, will have been invested by 2015), and a web of accountable national and local multi-disciplinary multiagency networks responsible for the planning, development and delivery of services. Initiatives ranged from the introduction of testing in specialist drug services through finger-prick blood sampling by nonclinical staff, to the setting of government targets to ensure rapid scale-up of antiviral therapy. The Plan was informed by comprehensive national monitoring systems, indicating the extent of the problem not just in terms of numbers infected, diagnosed and treated but also the more penetrative data on the number advancing to end-stage liver disease and death, and also through compelling modelling work demonstrating the potential beneficial impact of scaling-up therapy and the mounting cost of not acting. Achievements include around 50% increase in the proportion of the infected population diagnosed (38% to 55%); a sustained near two-and-a-half fold increase in the annual number of people initiated onto therapy (470 to 1050) with more pronounced increases among PWID (300 to 840) and prisoners (20 to 140); and reversing of an upward trend in the overall number of people living with chronic infection. The Action Plan has demonstrated that a Government-backed, coordinated and invested approach can transform services and rapidly improve the lives of thousands. Cited as ''an impressive example of a national strategy'' by the Global Commission on Drug Policy, the Scottish Plan has also provided fundamental insights of international relevance into the management of HCV among PWID.
BASE
Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience
Seven years have elapsed since the Scottish Government launched its Hepatitis C Action Plan – a Plan to improve services to prevent transmission of infection, particularly among people who inject drugs (PWID), identify those infected and ensure those infected receive optimal treatment. The Plan was underpinned by industrial scale funding (around £100 million, in addition to the general NHS funding, will have been invested by 2015), and a web of accountable national and local multi-disciplinary multi-agency networks responsible for the planning, development and delivery of services. Initiatives ranged from the introduction of testing in specialist drug services through finger-prick blood sampling by non-clinical staff, to the setting of government targets to ensure rapid scale-up of antiviral therapy. The Plan was informed by comprehensive national monitoring systems, indicating the extent of the problem not just in terms of numbers infected, diagnosed and treated but also the more penetrative data on the number advancing to end-stage liver disease and death, and also through compelling modelling work demonstrating the potential beneficial impact of scaling-up therapy and the mounting cost of not acting. Achievements include around 50% increase in the proportion of the infected population diagnosed (38% to 55%); a sustained near two-and-a-half fold increase in the annual number of people initiated onto therapy (470 to 1050) with more pronounced increases among PWID (300 to 840) and prisoners (20 to 140); and reversing of an upward trend in the overall number of people living with chronic infection. The Action Plan has demonstrated that a Government-backed, coordinated and invested approach can transform services and rapidly improve the lives of thousands. Cited as "an impressive example of a national strategy" by the Global Commission on Drug Policy, the Scottish Plan has also provided fundamental insights of international relevance into the management of HCV among PWID.
BASE